ProShare Advisors LLC Has $1.17 Million Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

ProShare Advisors LLC lifted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 44.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,925 shares of the company's stock after acquiring an additional 4,590 shares during the quarter. ProShare Advisors LLC's holdings in Prestige Consumer Healthcare were worth $1,165,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC boosted its position in shares of Prestige Consumer Healthcare by 346.3% in the third quarter. Barclays PLC now owns 92,444 shares of the company's stock worth $6,665,000 after buying an additional 71,730 shares during the period. SG Americas Securities LLC boosted its position in Prestige Consumer Healthcare by 18.8% during the 4th quarter. SG Americas Securities LLC now owns 5,996 shares of the company's stock worth $468,000 after acquiring an additional 947 shares during the period. Avior Wealth Management LLC grew its stake in Prestige Consumer Healthcare by 1,570.7% during the 4th quarter. Avior Wealth Management LLC now owns 8,554 shares of the company's stock valued at $668,000 after acquiring an additional 8,042 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Prestige Consumer Healthcare by 4.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 23,776 shares of the company's stock valued at $1,857,000 after purchasing an additional 975 shares during the period. Finally, Blue Trust Inc. lifted its position in shares of Prestige Consumer Healthcare by 24.8% in the fourth quarter. Blue Trust Inc. now owns 2,190 shares of the company's stock worth $158,000 after purchasing an additional 435 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now owns 17,157 shares of the company's stock, valued at $1,544,130. The trade was a 8.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Stock Performance

Shares of PBH traded down $1.00 during mid-day trading on Wednesday, hitting $84.88. The company's stock had a trading volume of 43,621 shares, compared to its average volume of 296,875. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04. The stock's 50-day moving average is $83.59 and its two-hundred day moving average is $82.36. The firm has a market capitalization of $4.19 billion, a PE ratio of 19.88, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The business had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. During the same period last year, the business earned $1.02 earnings per share. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PBH shares. Oppenheimer upped their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. Wall Street Zen raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Royal Bank of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. DA Davidson boosted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Finally, Canaccord Genuity Group raised their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.